MeiHua Holdings Group (600873) Q4 2025 earnings summary

Executive summary

• Achieved revenue of RMB 24.209 billion in 2025, down 3.43% year-over-year due to lower product prices despite higher sales volumes.

• Net profit attributable to shareholders rose 19.72% to RMB 3.281 billion, driven by non-recurring gains from the Kyowa acquisition.

• Completed acquisition and integration of Kyowa Hakko's food and pharmaceutical amino acid businesses, expanding into high-end pharmaceutical amino acids and precision fermentation.

• Enhanced global competitiveness and digital transformation, with MES systems implemented across core production bases.

Financial highlights

• Revenue: RMB 24.209 billion, down 3.43% year-over-year.

• Net profit attributable to shareholders: RMB 3.281 billion, up 19.72% year-over-year.

• Gross profit margin increased by 1.08 percentage points year-over-year.

• Basic EPS: RMB 1.17, up 24.47% year-over-year.

• Net cash flows from operating activities: RMB 4.009 billion, down 13.35% year-over-year.

Outlook and guidance

• Focus on becoming a leading enterprise in synthetic biology and expanding international presence.

• Plans to deploy AI-powered bio-intelligence systems and optimize global production capacity.

• 2026 business plan includes further digital transformation, talent development, and risk management.